Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects
Status:
Withdrawn
Trial end date:
2012-10-18
Target enrollment:
Participant gender:
Summary
This is an open-label, single centre, parallel group study to evaluate the safety and
pharmacokinetics of single oral doses of retigabine XR formulation in healthy adult Japanese
subjects. To compare the pharmacokinetic and safety profile, Caucasian subjects are also
incorporated. This study is intended to facilitate inclusion of Japanese patients in the
global phase III program for retigabine XR formulation.